Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2193-6382
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience ; volume:12 ; number:1 ; day:28 ; month:11 ; year:2022 ; pages:257-271 ; date:1.2023
Infectious diseases and therapy ; 12, Heft 1 (28.11.2022), 257-271, 1.2023
- Urheber
-
Tiseo, Giusy
Barbieri, Chiara
Galfo, Valentina
Occhineri, Sara
Matucci, Tommaso
Almerigogna, Francesco
Kalo, Jona
Sponga, Pietro
Cesaretti, Mario
Marchetti, Gabriele
Forniti, Arianna
Caroselli, Claudio
Ferranti, Simone
Pogliaghi, Manuela
Polidori, Marina
Fabiani, Silvia
Verdenelli, Stefano
Tagliaferri, Enrico
Riccardi, Niccolò
Suardi, Lorenzo Roberto
Carmignani, Claudia
Batini, Serena
Puccetti, Luca
Iapoce, Riccardo
Menichetti, Francesco
Falcone, Marco
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40121-022-00729-2
- URN
-
urn:nbn:de:101:1-2023033021015617696916
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tiseo, Giusy
- Barbieri, Chiara
- Galfo, Valentina
- Occhineri, Sara
- Matucci, Tommaso
- Almerigogna, Francesco
- Kalo, Jona
- Sponga, Pietro
- Cesaretti, Mario
- Marchetti, Gabriele
- Forniti, Arianna
- Caroselli, Claudio
- Ferranti, Simone
- Pogliaghi, Manuela
- Polidori, Marina
- Fabiani, Silvia
- Verdenelli, Stefano
- Tagliaferri, Enrico
- Riccardi, Niccolò
- Suardi, Lorenzo Roberto
- Carmignani, Claudia
- Batini, Serena
- Puccetti, Luca
- Iapoce, Riccardo
- Menichetti, Francesco
- Falcone, Marco
- SpringerLink (Online service)
Ähnliche Objekte (12)
Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5
Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab
Real-world analysis of safety, tolerability, and adherence to nirmatrelvir-ritonavir (paxlovid) in primary care COVID-19 outpatients
Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients
List of Out-Patients
List of Out-Patients
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study
Evaluation of the impact of lopinavir/ritonavir (LPV/r) and ritonavir (RTV) on QTcF: results of a thorough QT study
Pharmacovigilance of Drug–Drug Interactions with Nirmatrelvir/Ritonavir
Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge
Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5
Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab
Real-world analysis of safety, tolerability, and adherence to nirmatrelvir-ritonavir (paxlovid) in primary care COVID-19 outpatients
Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients
List of Out-Patients
List of Out-Patients
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study
Evaluation of the impact of lopinavir/ritonavir (LPV/r) and ritonavir (RTV) on QTcF: results of a thorough QT study
Pharmacovigilance of Drug–Drug Interactions with Nirmatrelvir/Ritonavir
Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge
Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5
Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab
Real-world analysis of safety, tolerability, and adherence to nirmatrelvir-ritonavir (paxlovid) in primary care COVID-19 outpatients
Nirmatrelvir plus ritonavir reduces COVID-19 hospitalization and prevents long COVID in adult outpatients
List of Out-Patients
List of Out-Patients
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study
Evaluation of the impact of lopinavir/ritonavir (LPV/r) and ritonavir (RTV) on QTcF: results of a thorough QT study
Pharmacovigilance of Drug–Drug Interactions with Nirmatrelvir/Ritonavir
Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge